The exercise price for warrants of series TO 2 has been set to SEK 1.50 per new share

Oct 10, 2023, 20:30

Carbiotix AB ("Carbiotix" or "the Company") hereby announces that the exercise price for the warrants of series TO 2 (”TO 2”), which were issued in connection with the rights issue of units the Company executed earlier during 2023, has been set. The exercise price for TO 2 has been set to SEK 1.50 per share and the exercise period commences on October 12th, 2023.

In June 2023, Carbiotix carried out a rights issue that brought the Company approximately SEK 12 million before issue costs. Through the rights issue, 3,190,188 warrants of series TO 2 were issued. Each TO 2 entitles the holder to subscribe for one (1) new share in Carbiotix during the exercise period, which runs October 12-26, 2023. The exercise price for TO 2 has been set at SEK 1.50 per share, which is the lowest within the range established in connection with the Company's rights issue of units. In the event of full utilization of warrants of series TO 2, approximately SEK 4.8 million will be added to the Company before issue costs.

Upon full utilization of TO 2, the number of shares in Carbiotix will increase by 3,190,188 shares to a total of 23,926,417 shares and the share capital will increase by SEK 319,018.80 to SEK 2,392,641.70. The dilution at full utilization amounts to approximately 13.3 percent of the capital and votes.

Complete terms and instructions for warrants of series TO 2 are available on the Company's website ( An information sheet containing summary information about the warrant exercise will be available on Carbiotix, Sedermera Corporate Finance AB's ( and Nordic Issuing AB's ( respective websites in connection with the initiation of the exercise period.

Important dates
• 12 October 2023: Exercise period commences
• 24 October 2023: Last day of trading in TO 2
• 26 October 2023: Exercise period ends
• 27 October 2023: Planned date for publication of outcome of the exercise
• 13 November 2023: Planned date for chage from interim shares to shares

In connection with the warrant exercise, Carbiotix has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.

For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10

For more information, please contact:
Erik Deaner, CEO
Tel: +46 (0)73-867 30 85

About Carbiotix
Carbiotix AB (CRBX) ( is an award-winning biotechnology company pioneering microbiome health through a portfolio of prebiotic modulators and diagnostic testing services.

Go Back